NewsNew Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →Read more →
NewsTarget RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024Read more →Read more →
NewsTarget RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver DiseasesRead more →Read more →
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →
Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024Read more →
Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver DiseasesRead more →
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic DefinitionsRead more →
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024Read more →
AGA Announces New Partnership with Target RWE to Gather Real World Data on Eosinophilic Esophagitis (EoE)Read more →
Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024Read more →
Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver DiseasesRead more →
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHRead more →
Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality CollaborativeRead more →
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis PopulationRead more →
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, DiscontinuationRead more →
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology ReportingRead more →
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger PatientsRead more →
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart DiseaseRead more →
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD PopulationRead more →
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver BiopsyRead more →
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry PartnershipsRead more →
TARGET PharmaSolutions to Advance Dermatology Research, including Atopic Dermatitis, through New CollaborationRead more →
TARGET PharmaSolutions Announces Partnership with Bristol Myers Squibb to Advance Inflammatory Bowel Disease (IBD) ResearchRead more →
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead SciencesRead more →
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASHRead more →
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World DataRead more →
